 This single center, single arm open label study is designed to assess the safety and efficacy of using high dose of Icotinib Conmana as a way to treat patients with non-small cell lung cancer that progressed after routine gefitinib therapy by progression-free survival, as well as overall survival and disease control rate. The adverse events and adverse reaction are evaluated as well. 